Skip to Content

Proben-C (colchicine / probenecid) Disease Interactions

There are 12 disease interactions with Proben-C (colchicine / probenecid):

Major

Colchicine (applies to Proben-C) bone marrow suppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of colchicine should be used with caution in patients with bone marrow suppression. Patients on long term therapy may require periodic blood counts.

References

  1. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol 18 (1991): 264-9
  2. Vedia C, Mascort JJ, Carrasco I, Olive A "Colchicine and thrombopenia." Clin Exp Rheumatol 11 (1993): 458
  3. Liu YK, Hymowitz R, Carroll MG "Marrow aplasia induced by colchicine. A case report." Arthritis Rheum 21 (1978): 731-5
  4. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
  5. Ferrannini E, Pentimone F "Marrow aplasia following colchicine treatment for gouty arthritis." Clin Exp Rheumatol 2 (1984): 173-5
  6. Stanley MW, Taurog JD, Snover DC "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol 2 (1984): 167-71
  7. Finklestein M, Goldman L, Grace ND, Foley M, Randall N "Granulocytopenia complicating colchicine therapy for primary biliary cirrhosis." Gastroenterology 93 (1987): 1231-5
  8. Neuss MN, McCallum RM, Brenckman WD, Silberman HR "Long-term colchicine administration leading to colchicine toxicity and death." Arthritis Rheum 29 (1986): 448-9
View all 8 references
Major

Colchicine (applies to Proben-C) cardiac dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

The use of colchicine should be used with caution in patients with cardiac dysfunction. The possibility of cumulative effects of colchicine is increased in these patients.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (applies to Proben-C) DIC

Major Potential Hazard, High plausibility. Applicable conditions: Disseminated Intravascular Coagulation

Colchicine should be used with caution in patients with disseminated intravascular coagulation. Debilitated patients have an increased risk of developing colchicine toxicity.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Vedia C, Mascort JJ, Carrasco I, Olive A "Colchicine and thrombopenia." Clin Exp Rheumatol 11 (1993): 458
Major

Colchicine (applies to Proben-C) electrolyte disturbances

Major Potential Hazard, High plausibility. Applicable conditions: Hyponatremia, Hypokalemia, Electrolyte Abnormalities

Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (applies to Proben-C) liver disease

Major Potential Hazard, High plausibility.

The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). Caution is recommended when prescribing colchicine to these patients.

References

  1. Kocak N, Yuce A, Gurakan F, Ozen H, Gogus S, Kale G, Caglar M "Colchicine in the treatment of hepatic fibrosis in children." Am J Gastroenterol 91 (1996): 179-80
  2. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L "A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report." J Hepatol 5 (1987): 1-7
  3. Stanley MW, Taurog JD, Snover DC "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol 2 (1984): 167-71
  4. Zifroni A, Schaffner F "Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy." Hepatology 14 (1991): 990-3
  5. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV "Colchicine clearance is impaired in alcoholic cirrhosis." Hepatology 14 (1991): 1013-5
  6. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
  7. Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol 19 (1992): 494-6
View all 7 references
Major

Colchicine (applies to Proben-C) renal dysfunction

Major Potential Hazard, High plausibility.

Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Colchicine dosing must be individualized according to the patient's renal function. Caution must be exercised when colchicine therapy is instituted in these patients. Monitoring creatinine function is recommended in patients on long term therapy.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Said R, Hamzeh Y, Tarawneh M, el-Khateeb M, Abdeen M, Shaheen A "Rapid progressive glomerulonephritis in patients with familial Mediterranean fever." Am J Kidney Dis 14 (1989): 412-6
  3. Older SA, Finbloom DS, Pezeshkpour GH "Colchicine myoneuropathy and renal dysfunction." Ann Rheum Dis 51 (1992): 1343-4
  4. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol 18 (1991): 264-9
View all 4 references
Major

Probenecid (applies to Proben-C) blood dyscrasias

Major Potential Hazard, Moderate plausibility. Applicable conditions: Anemia, Bone Marrow Depression/Low Blood Counts

The manufacturer does not recommend the use of probenecid in patients with known blood dyscrasias. Aplastic anemia, leukopenia, hemolytic anemia and other anemia have been reported infrequently during administration of probenecid. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency may increase the risk of probenecid-induced hemolytic anemia.

References

  1. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
  2. Sosler SD, Behzad O, Garratty G, et al "Immune hemolytic anemia associated with probenecid." Am J Clin Pathol 84 (1985): 391-4
  3. Kickler TS, Buck S, Ness P, et al "Probenecid induced immune hemolytic anemia." J Rheumatol 13 (1986): 208-9
  4. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
View all 4 references
Major

Probenecid (applies to Proben-C) dehydration

Major Potential Hazard, High plausibility. Applicable conditions: Diarrhea, Vomiting

Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during therapy. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of uric acid kidney stones and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
  2. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Major

Probenecid (applies to Proben-C) uric acid nephrolithiasis

Major Potential Hazard, High plausibility. Applicable conditions: History - Nephrolithiasis, Gouty Nephropathy

The use of probenecid is not recommended in patients with a history of uric acid nephrolithiasis or a urinary urate excretion greater than 750 mg/24 hr. Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during treatment. In general, a fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline urine is also desirable.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
  2. Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Moderate

Colchicine (applies to Proben-C) rhabdomyolysis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Caution must be exercised when colchicine therapy is instituted in these patients.

Moderate

Probenecid (applies to Proben-C) PUD

Moderate Potential Hazard, Low plausibility. Applicable conditions: Peptic Ulcer, History - Peptic Ulcer

The manufacturer states that probenecid should be used with caution in patients with a history of peptic ulcer. Uricosuric agents can cause upper gastrointestinal irritation and aggravate or reactivate peptic ulcer. However, these effects have primarily been reported with another uricosuric agent, sulfinpyrazone. GI effects associated with probenecid are usually limited to nausea, vomiting, and anorexia.

References

  1. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
Moderate

Probenecid (applies to Proben-C) renal dysfunction

Moderate Potential Hazard, High plausibility.

Probenecid may not be effective in patients with chronic renal insufficiency, particularly when glomerular filtration rate is 30 mL/min or less. Probenecid has been used in patients with some renal impairment but dosage requirements may be increased.

References

  1. Scott JT, O'Brien PK "Probenecid, nephrotic syndrome, and renal failure." Ann Rheum Dis 27 (1968): 249-52
  2. "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.

Proben-C (colchicine / probenecid) drug interactions

There are 381 drug interactions with Proben-C (colchicine / probenecid)

Proben-C (colchicine / probenecid) alcohol/food interactions

There is 1 alcohol/food interaction with Proben-C (colchicine / probenecid)

More about Proben-C (colchicine / probenecid)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.